Table 1.
Top pathways and associated networks identified by pathway analysis for the hippocampus following olanzapine treatment
| (a) Top canonical pathways (Genes with increased methylation) | P- value | No of molecules a |
|---|---|---|
| Dopamine-DARPP32 feedback in cAMP signalling |
1.65 × 10–3 |
20/157 (0.127) |
| CD27 signalling in lymphocytes |
2.42 × 10–4 |
11/54 (0.204) |
| Oestrogen-mediated S-phase entry |
2.56 × 10–3 |
6/26 (0.231) |
| Role of JAK2 in hormone-like cytokine signalling |
3.38 × 10–3 |
7/34 (0.206) |
|
Associated network functions |
|
|
| Metabolic disease, endocrine system and developmental disorders |
35 |
|
| Cell cycle, cellular growth and proliferation, cell death |
24 |
|
| Molecular transport, neurological disease, cell-to-cell signalling |
10 |
|
|
(b) Top canonical pathways (Genes with decreased methylation) |
P-
value |
No of molecules |
| CDC42 signalling |
2.52 × 10–3 |
11/131 (0.084) |
| Prostanoid biosynthesis |
2.55 × 10–3 |
3/9 (0.333) |
| Calcium signalling |
5.92 × 10–3 |
12/178 (0.067) |
| D-myo-inositol (1,3,4,5,6)-tetrakisphosphatebiosynthesis |
6.18 × 10–3 |
8/48 (0.167) |
|
Associated network functions |
|
|
| Developmental disorder, cell death and survival, cellular development |
12 |
|
| Molecular transport, nervous system development and function |
10 |
|
| Carbohydrate metabolism, cell morphology, lipid metabolism |
9 |
|
| Cellular development, skeletal, muscular and cardiovascular system development and function | 8 | |
aFor the top canonical pathways, the ratio is the number of molecules in a given pathway that meet the cut-off (P ≤ 0.01) divided by the total number of molecules in the pathway.